Join Prof Elliot Tapper as we discuss how to manage muscle cramps in cirrhosis.

Today's article: Muscle cramps in cirrhosis:

https://journals.lww.com/cld/pages/articleviewer.aspx?year=2024&issue=01010&article=00004&type=Fulltext

Join Dr Megan van Niekerk as she discusses with Dr Elizabeth Goode on managing cholestasis of pregnancy.

Article today: Intrahepatic cholestasis of pregnancy

https://journals.lww.com/cld/fulltext/2024/01010/intrahepatic_cholestasis_of_pregnancy.16.aspx

Join Dr Shamya Putta as she discusses with Dr Rajit Gilhotra on endohepatology covering endoscopic guided biopsies and portal pressure measurements.

Article: Recent advances in clinical practice endohepatology: the endoscopic liver rush

https://gut.bmj.com/content/74/11/1916.long

Join us as we discuss how to manage HPS with Dr Michael Krowka.

Learning points: Monitoring HPS, Supplemental oxygen, garlic capsules, liver transplantation and managing post transplantation.

ILTS guidelines: https://pubmed.ncbi.nlm.nih.gov/27326810/

Outcomes post liver transplantation: https://pubmed.ncbi.nlm.nih.gov/30487203/

Join Dr Davis from the RBWH as we discuss SIRT, radiation segmentectomy when treating HCC.

Covering response rates, curative vs palliative therapy and steps to performing SIRT

For further reading check out: https://pubmed.ncbi.nlm.nih.gov/38495257/

Join Prof Tsochatzis as we discuss MASLD Pathway, covering who should be screened, sensitivity of ultrasound, intrpreting iron studies and the impact of alcohol.

Also check out The Lancet review article - Screening for advanced steatotic liver disease - https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00097-4/abstract

Join Prof Emmanuel Tsochatzis as we discuss on interpreting and utilising NITs in assessing MASLD.

Detecting at-risk steatotic liver disease and liver fibrosis in the community: https://journals.lww.com/hep/fulltext/9900/detecting_at_risk_steatotic_liver_disease_and.1285.aspx

Join Dr Rohit Gupta as we discuss second line treatment for PBC covering treatment, impact on symptoms, advanced cirrhosis and managing patients on fenofibrate.

With Elafibranor and Seladelpar changing the landscape perfect time to learn more.

Elafibranor: https://www.nejm.org/doi/full/10.1056/NEJMoa2312100

Seladelpar:

https://www.nejm.org/doi/10.1056/NEJMoa2312100?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed